Kynapid Gets Panel Endorsement For Narrow Approval Due To Small Data Set
Executive Summary
A restricted indication was strongly recommended by Cardiovascular and Renal Drugs Advisory Committee members to offset the uncertainty of adverse events with Astellas/Cardiome's Kynapid (vernakalant), especially since the atrial fibrillation product will likely be used in critical care situations like emergency rooms rather than by specialists
You may also be interested in...
Cardiome/Astellas' Kynapid Approval Seems Likely For Limited Indication, If Additional Trial Holds Up
Atrial fibrillation drug has been languishing after "approvable" letter - but approval now seems in the cards for limited indication.
Cardiome/Astellas Kynapid Aiming For Limited Use, With New Trial
Narrowing the indication for Cardiome/Astellas' Kynapid (vernakalant) alone was not enough to secure an approval for the atrial fibrillation therapy - Astellas will now run an additional Phase III clinical trial to prospectively study the narrower population that is the new target for approval: patients with recent onset a-fib who do not have a history of heart failure
Cardiome/Astellas Kynapid Aiming For Limited Use, With New Trial
Narrowing the indication for Cardiome/Astellas' Kynapid (vernakalant) alone was not enough to secure an approval for the atrial fibrillation therapy - Astellas will now run an additional Phase III clinical trial to prospectively study the narrower population that is the new target for approval: patients with recent onset a-fib who do not have a history of heart failure